Developing new methods to target hard-to-drug proteins for various diseases
Activity-Based DNA-Encoded Library Technology
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA-IRVINE · NIH-11002265
This study is exploring new ways to find medicines that can help treat tough diseases like AIDS and cancer by targeting proteins that are usually hard to reach, and it aims to discover new treatments that could make a real difference for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA-IRVINE (nih funded) |
| Locations | 1 site (IRVINE, UNITED STATES) |
| Trial ID | NIH-11002265 on ClinicalTrials.gov |
What this research studies
This research focuses on overcoming the challenges of drug discovery for proteins that are difficult to target, known as 'undruggable' proteins. By utilizing a novel approach that targets translation intermediates, or ribosome nascent chains, the project aims to identify small molecules that can selectively inhibit protein synthesis. The methodology involves high-throughput screening of DNA-encoded libraries to discover new bioactive compounds that could lead to effective treatments for conditions like AIDS and cancer. Patients may benefit from the development of new therapies that target these previously inaccessible proteins.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with conditions related to AIDS or cancer who are seeking new treatment options.
Not a fit: Patients with conditions that are not related to the target diseases of AIDS or cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments for diseases that currently have limited options, such as AIDS and certain cancers.
How similar studies have performed: While the approach of targeting undruggable proteins is innovative, similar methodologies have shown promise in preliminary studies, indicating potential for success.
Where this research is happening
IRVINE, UNITED STATES
- UNIVERSITY OF CALIFORNIA-IRVINE — IRVINE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PAEGEL, BRIAN M — UNIVERSITY OF CALIFORNIA-IRVINE
- Study coordinator: PAEGEL, BRIAN M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, Anti-Cancer Agents, anti-cancer drug